Key result
This is a study protocol for a randomized, placebo-controlled trial of 228 patients to evaluate Qishen Yiqi dropping pills for CHD complicating chronic HFrEF; no results are available.
Why the study?
Heart failure is a common complication of coronary heart disease, and this study aims to evaluate the clinical efficacy, safety, and optimal effective dose of Qishen Yiqi dropping pills in patients with CHD complicating HFrEF.
Population
228 individuals with CHD complicating HFrEF from 16 hospitals in China
Comparison
Low-dose QSYQ vs high-dose QSYQ vs placebo
Design
Randomized, double-blind, placebo-controlled, multicenter phase II clinical trial
Follow-up
12 weeks
Authors
Loading...
RCT (n=228)
Double-blind
1:1:1
Yes
He et al. (2023) conducted an RCT in Coronary heart disease complicating chronic heart failure with reduced ejection fraction (HFrEF) (n=228). Qishen Yiqi dropping pills (QSYQ) vs. placebo was evaluated on 6-Minute Walk Test (6MWT) at Week 12. This is a study protocol for a randomized, placebo-controlled trial of 228 patients to evaluate Qishen Yiqi dropping pills for CHD complicating chronic HFrEF; no results are available.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: